表紙
市場調查報告書

阿茲海默症:競爭情形

Alzheimer's Disease: Competitive Landscape to 2026

出版商 GlobalData 商品編碼 673448
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
阿茲海默症:競爭情形 Alzheimer's Disease: Competitive Landscape to 2026
出版日期: 2018年06月30日內容資訊: 英文 49 Pages
簡介

本報告提供阿茲海默症相關臨床研究的最新趨勢相關調查,各疾病、治療藥概要,地區臨床實驗情形,開發平台的評估,研究的進展,主要企業趨勢等資料彙整。

第1章 序文

  • 目錄
  • 簡稱一覽
  • 相關調查
  • 出版預定的相關調查

第2章 摘要整理

  • 主要的調查成果
  • 主要的活動

第3章 簡介

  • 報告範圍
  • 疾病概要與流行病學

第4章 開發平台評估

  • 開發平台概要
  • 開發平台的明細:各地區、國家
  • 開發平台的明細:各分子類型、標的
  • 藥品檢討
  • 臨床開發中的產品

第5章 臨床實驗的評估

  • 臨床試驗概要
  • 臨床實驗的主要贊助商
  • 臨床實驗的明細:各地區
  • 治療領域
  • 病患註冊

第6章 商業性評估

  • 主要上市產品
  • 現在活躍中、預期今後活躍的企業

第7章 競爭環境分析

  • 活動區分
  • 美國
  • 歐盟5國
  • 日本
  • 中國

第8章 附錄

目錄
Product Code: GDHC011CL

Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The degeneration of neurons starts in the brainstem before progressing to the hippocampus, frontal lobe, amygdala, parietal lobe, and temporal lobe. The cause of AD is unknown, but it appears to be multifactorial, with most research aimed at the AB peptides and tau proteins. The irregular clearance and metabolism of these proteins are likely contributors to the presentation of the disease. The risk of developing AD is believed to be determined by a combination of genetic, metabolic, behavioral, and environmental factors.

This report provides an assessment of the pipeline, clinical, and commercial landscape of AD. Overall, GlobalData expects new drug approvals to drive AD market growth over the next decade (2016-2026).

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -

  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment: leading marketed products, current and future players
  • Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global AD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Preface 2

  • 1.1 Table of Contents 2
  • 1.2 Abbreviations 3
  • 1.3 Related Reports 4
  • 1.4 Upcoming Related Reports 5

2. Executive Summary 6

  • 2.2 Key Findings 7
  • 2.2 Key Events 8

3. Introduction 9

  • 3.1 Report Scope 10
  • 3.2 Disease Overview and Epidemiology 12

4. Pipeline Assessment 15

  • 4.1 Pipeline Overview 16
  • 4.2 Pipeline Breakdown by Region/Country 18
  • 4.3 Pipeline Breakdown by Molecule Type and Target 19
  • 4.4 Drug Review Designations 20
  • 4.5 Products in Clinical Development 21

5. Clinical Trial Assessment 23

  • 5.1 Clinical Trials Overview 24
  • 5.2 Top Sponsors of Clinical Trials in AD 25
  • 5.3 Trial Breakdown by Region 27
  • 5.4 Therapy Area Perspective 28
  • 5.5 Enrollment Analytics 29

6 Commercial Assessment 32

  • 6.1 Leading Marketed Products 33
  • 6.2 Current & Future Players 34

7. Competitive Landscape Analysis (2016-2026) 35

  • 7.1 Events Classification Overview 36
  • 7.2 US 37
  • 7.3 5EU 38
  • 7.4 Japan 39
  • 7.5 China 40

8 Appendix 42

  • 8.1 Sources 43
  • 8.2 Methodology 45
  • 8.3 Key Events Included in the Analysis 46
  • 8.4 About the Authors 47
  • 8.5 About GlobalData 50
  • 8.6 Disclaimer 52